In spite of multimodal management including aggressive surgery and chemotherapy, the prognosis of advanced ovarian cancer (AOC) remains poor. Multicycle high-dose chemotherapy (HDC) with haematopoietic stem cell (HSC) support has been shown to be a promising procedure in various cancers including AOC. We conducted a phase II multicentre study to evaluate feasibility, toxicity and efficacy of post-operative front-line sequential HDC with HSC support in AOC. Thirty four patients with stage IIIC/IV received a post-operative sequential combination of high-dose cyclophosphamide/epirubicin (D1, D21) with HSC harvesting, high-dose carboplatin (D42, D98) followed by HSC infusion, and dose-dense paclitaxel (D63, D77, D119, D133). Rh-G-CSF (filgrastim) was administered following all cycles. Primary endpoint was pathological complete response rate (pCR). Thirty patients received at least 7 of the scheduled 8 cycles. Haematological toxicity was significant but manageable. Grade 3/4 extra-haematopoietic toxicities were relatively uncommon and reversible. No toxicity-related death was observed. The observed pCR was 37% and did not reach the initial endpoint. Post-operative front-line sequential HDC in AOC is feasible and safe in a multicentre setting. The observed pCR does not support a clear advantage over conventional treatment. This approach remains an experimental strategy to further optimise and validate.
Introduction
In spite of multidisciplinary management including aggressive surgical cytoreduction and post-operative chemotherapy, five-year survival rates in advanced ovarian cancer (AOC) do not exceed 30%. 1 In these patients, current standard chemotherapeutic agents include platinum compounds and taxanes, the combination of which allows a high clinical response rate to be obtained (70 to 80%), including 30 to 40% of pathological complete response, with a median progression-free survival of 15 to 18 months and a median overall survival of 35 to 38 months. 2, 3 Ovarian cancer was considered early on as a good model for high-dose chemotherapy (HDC): it is a chemosensitive disease with a documented dose-response effect for alkylating agents and platinum compounds, 4, 5 although no significant clinical benefit has been shown for modest increases in dose of platinum compounds. In recurrent or refractory disease, such a therapeutic approach was shown to induce significant response rates, but duration of response was short and long term progression-free survival was uncommon. 6, 7 Recently, some evidence suggested that HDC administered as consolidation after conventional chemotherapy, in surgically verified responding patients might significantly improve long term outcome. [8] [9] [10] However, this putative benefit is restricted by definition to a selected patient population, i.e. responding patients, while excluding patients initially resistant to conventional dose. In addition, administration of a single HDC cycle, although very effective in a low burden setting, might not be sufficient to eradicate the 'last cell' and prevent the disease relapse.
An alternative method of manipulating the dose-effect concept may be to deliver HDC as front-line treatment and as dose-dense and rapidly cycled sequential drug combinations. Using sequential administration of HDC regimen based on various anti-tumour agents with different action mechanisms may combine dose-density and dose-intensity concepts while limiting the development of drug resistance.
In addition, a front-line strategy may allow intensive treatment to be applied to the entire population, without previous patient selection and before emergence of resistant clones potentially induced by initial drug exposure. This could result in increasing the absolute number of responses, including pathological response, and ultimately translate to significant improvement in disease-free and overall survival.
Recent technological innovations in haematopoietic support, including haematopoietic growth factors and peripheral blood stem cells, allow repeated and rapidly cycled HDC to be administered with acceptable toxicity and, recently, on an outpatient basis. Safety of this kind of approach has been widely described by different pilot studies in various malignancies, including ovarian cancer, and promising antitumour activity was reported. [12] [13] [14] [15] [16] [17] Consequently, we conducted a multicentre phase II study investigating the effectiveness of sequential HDC in advanced ovarian cancer, including sequential use of high-dose cyclophosphamide, epirubicin, carboplatin and paclitaxel, with HSC support. The primary endpoint was pathological complete response rate. Secondary endpoints included toxicity and feasibility.
Patients and methods

Eligibility
The protocol was approved by an independent ethics committee and all patients had to give written informed consent according to all required guidelines.
Patients were enrolled from July 1998 through April 2000 in this phase II study involving 9 French cancer centres and/or hospitals. To be eligible, patients were to have pathological diagnosis of stage IIIC or IV epithelial ovarian carcinoma according to International Federation of Gynaecologic and Obstetrics (FIGO) criteria, whatever the type of initial debulking surgery. Additionally, patients were to have no prior chemotherapy, a Karnovsky index at least equal to 60%, a life expectancy of more than 3 months. Age had to be between 18 and 61 years.
A comprehensive medical history and physical examination including complete blood count, biochemical profile, viral titers (hepatitis A, B, C, CMV, HIV) ECG, left ventricular ejection fraction (LEVF) measurement, chest X-rays, CT scan and Ca-125 were performed before initiating treatment. Patients were to have adequate bone marrow (absolute neutrophil count 41.5 G/l, and platelets 4100 G/l), hepatic (total bilirubin and transaminases p2 times the institutional upper limit of normal), renal function (serum creatinine p1.25 times the institutional upper limit of normal) and heart function (LVEF450% by echographic or isotopic measurement).
Exclusion criteria included borderline histology, uncontrolled brain metastasis, peripheral neuropathy Xgrade II (NCI/EORTC criteria), known HIV infection, active viral hepatitis, history of any cancer (other than in situ cervical cancer or skin carcinomas which had been given curative treatment), large bowel resection, active infection, any serious medical conditions and social, geographic or psychological conditions preventing full medical follow-up.
Treatment Plan and drug administration
Projected treatment included sequential combination of ( Figure 1 ): 2 cycles of high-dose cyclophosphamide and epirubicin (with Rh-G-CSF support and mobilisation of HSC) at 21-day interval 2 cycles high-dose carboplatin with HSC and Rh-G-CSF support alternated with 4 cycles of dose-dense paclitaxel with Rh-G-CSF support. High-dose cyclophosphamide/epirubicin and mobilisation of stem cells: Chemotherapy was scheduled to begin within 4 to 6 weeks after initial surgery. Patients received cyclophosphamide 3000 mg/m 2 as a 1-h perfusion on day 1 and 2 and epirubicin 100 mg/m 2 as a 1-h perfusion on day 1. Hyperhydration, uromitexan and 5 HT3 antagonists/ steroids were administered. Starting on day 5, Rh-G-CSF (Filgrastim) 5 mg/kg was administered daily until the day before the last apheresis. Apheresis started when blood CD34 þ was 420/ml and a minimum of 5.5 Â 10 6 CD34 þ cells/kg had to be collected. Aphereses were performed as previously described. 12 Cells were divided into at least two bags and stored in liquid nitrogen, to allow infusion of a minimum of 2 Â 10 6 CD34 þ cells/kg after high-dose carboplatin.
A second cycle of cyclophosphamide/epirubicin þ Rh-G-CSF was scheduled on day 21. This cycle was also used to mobilize additional HSC in case of insufficient apheresis after cycle 1. Rh-G-CSF was administered until absolute neutrophil count was 40.5 G/l on two consecutive days, or until the day before the last apheresis.
High-dose carboplatin
On day 42 and day 98, patients received carboplatin AUC 18 mg/ml/min in 1-h perfusion. Carboplatin dosing was based on the Chatelut formula. 18 Hyperhydration, and 5 HT3 antagonists/steroids were administered. Infusion of HSC was performed 72 h after the end of carboplatin Front-line sequential HDC in ovarian cancer A Gonc¸alves et al perfusion. Rh-G-CSF was administered daily from the day of HSC infusion until ANC40.5 G/l on two consecutive days.
Paclitaxel administration
Paclitaxel 200 mg/m 2 was administered on an outpatient basis as a 3-h perfusion on day 63, 77, 119 and 133. Standard premedication was given prior to paclitaxel and Rh-G-CSF was administered daily between day 7 and day 11 after paclitaxel.
Dose adaptations
No dose reduction was allowed. Chemotherapy was administered if ANC40.5 G/l and platelet 450 G/l. If haematological requirements were not reached, treatment was delayed until recovery for a maximum of 2 weeks, before trial withdrawal. Patients experiencing grade 4 neurological toxicity were withdrawn from the trial. In case of grade 3 neurological toxicity or grade 3/4 mucositis, treatment was delayed until recovery of a grade p2 for a maximum of 2 weeks, before trial withdrawal.
Supportive care
Patients were allowed to be managed on an outpatient basis after high-dose chemotherapy, including HSC infusion, and were readmitted only in case of fever or degradation of their clinical conditions. Complete blood count and biochemical profile was obtained before each drug administration. Weekly clinical exam and three-weekly complete blood count were performed. No prophylactic antibiotics were administered. All patients received red blood cells when haemoglobin was less than 80 g/l and a single-donor platelet transfusion when the platelet count was less than 20 G/l with any bleeding.
Follow-up
All patients receiving at least the cyclophosphamide/ epirubicin day 1 were considered assessable for toxicity. Toxicity was graded using NCI common toxicity criteria. 19 Clinical tumour assessments were performed 4 to 6 weeks after the last course, by identical means used for initial evaluation, including CT scan and Ca-125 measurements.
Second look surgery (SLS) for pathological response assessment had to be performed between 4 and 8 weeks after the last cycle, in patients with clinical complete response by imagery and tumour markers measurements, i.e. absence of any measurable or evaluable lesions and normal Ca-125 levels. Second look coelioscopy was tolerated as long as it was converted in laparotomy in case of complete remission. Biopsies of any visible residual lesion, biopsy on initial sites of disease, and systematic peritoneal biopsies were required as well as systematic peritoneal cytology. Pathological complete response (pCR) was defined as no evidence of residual tumour, negative systematic biopsies and negative peritoneal cytology. Macroscopic complete response (mCR) was defined as no evidence of residual tumour but positive systematic biopsies. Persistent disease was defined as any macroscopic residual tumour.
Statistical design
The principal endpoint was the number of pathological complete response after SLS. The number of patients to enter in the study was calculated using a Fleming plan 20 with three steps. The objective was to detect a pCR of 50% or more with a beta risk of 0.18 and an alpha risk of 0.05, considering as unacceptable a pCR of 30% or less. These rates were determined based on pCR reported with standard platinum/taxanes based regimen. Three interim analyses were planned: after evaluation of 15 patients: if 3 or less pCR were observed, the trial had to be stopped and treatment efficacy hypothesis rejected; if 9 or more pCR were observed the trial had to be stopped and treatment efficacy hypothesis retained. In any other cases, 15 additional patients had to be included. after evaluation of 30 patients: if 11 or less pCR were observed, the trial had to be stopped and treatment efficacy hypothesis rejected; if 15 or more pCR were observed the trial had to be stopped and treatment efficacy hypothesis retained. In any other cases, 15 additional patients had to be included. after evaluation of 45 patients: if 19 or less pCR were observed, treatment efficacy hypothesis would be rejected; if 20 or more pCR were observed treatment efficacy hypothesis would be retained.
Cause specific survival (OS) was calculated from the date of first surgery, disease-related death being scored as an event with censoring of other patients at the date of last follow-up or of non-disease-related death. Disease-free survival (DFS) was also calculated from the date of first surgery, first recurrence being scored as an event, with censoring of other patients at the time of last follow-up or death. OS and DFS curves were drawn using Kaplan and Meier 21 estimates. Curves were compared by the log-rank test. 22 For graphical presentation, follow-up was truncated at 60 months Survival rates are presented with their 95% confidence intervals (CI). Analyses were performed using SAS Version 8.2 (SAS Institute. Inc.). Table 1) A total of 35 patients have been entered in the trial. Five more patients than projected were included since 5 patients were not assessable for efficacy, due to early withdrawal for toxicity before receiving the first course of paclitaxel (n ¼ 3), misdiagnosis (n ¼ 1) and very early progressive disease (n ¼ 1). Thirty four eligible patients were analysed (one patient with a final diagnosis of neuroendocrine carcinomas was removed from analysis). Median age was 50 (31 to 61) and median Karnovski index was 90% (60 to 90). There was a majority of papillary serous carcinomas, and nearly 30% of patients were stage IV disease. Only 3 patients had no residual disease after initial surgery and 50% of patients were not optimally debulked after initial surgery, with a residual tumour volume X5 mm.
Results
Patient demographics (
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Treatment delivery
Of 34 eligible patients, 6 did not receive full treatment, 3 of them being withdrawn before initiation of the first paclitaxel course, due to toxicity. One patient was withdrawn from the study for rapidly progressive disease, leading to death on day 4 of the first cycle. Two additional patients did not receive the last paclitaxel course, one due to progressive disease, the other one due to the lack of haematological (neutrophils) recovery.
HSC collection was completed after the first cyclophosphamide/epirubicin cycle for 31 out of 33 assessable patients. The 2 remaining patients were not collected after cycle 2: one due to delayed haematological recovery and failure to reach a sufficient number of circulating CD34 þ cells, the other one due to severe sepsis. Both were withdrawn from the study.
The median number of collected CD34 þ /kg was 24 Â 10 6 . Two patients have 5.3 and 5.2 Â 10 6 CD34 þ /kg collected, respectively but were allowed to continue on program as long as it was possible to infuse at least 1.5 Â 10 6 CD34 þ /kg for cycle 3 and 6 of carboplatin. Median number of infused HSC was 6.8 Â 10 6 and 11.2 Â 10 6 CD34 þ /kg after cycle 3 and 6, respectively.
Less than 20% (6 of 33) of patients received a delayed cycle 2 for a median of 6 days, essentially due to febrile neutropenia or lack of haematological recovery. Carboplatin was administered on time for 70% (22 of 31) and 86% (26 of 30) of patients on cycle 3 and 6, respectively. Reported reasons for delay included mainly lack of haematological recovery. At least 75% of patients received paclitaxel on scheduled time, ranging between 100% on cycle 4 (30 of 30) and 76% on cycle 7 (23 of 30) ( Table 2) . Toxicity Three patients were withdrawn from the study after experiencing toxicity: one patient failed to reach an adequate platelet recovery 5 weeks after cycle 2. Another patient was withdrawn after a severe sepsis without bacteriological documentation following cycle 2. The third patient presented a serious degradation of general condition, with pneumonia and reversible grade 3 central neurological alteration, including confusion and somnolence, following first high-dose carboplatin. No toxicity-related death was observed.
Haematological toxicity ( Table 3) . As expected, haematological toxicity was severe following dose-dense chemotherapy regimen (cycle 1, 2, 3 and 6). Febrile neutropenia requiring hospitalisation and IV antibiotics was experienced in about 75% of patients after cycle 1 and 2, and in about 50% of patients following high-dose carboplatin. However, median duration of grade 4 neutropenia was relatively short (3-5 days). By contrast, paclitaxel dose-dense cycles 
Efficacy
Response (Table 4) . Primary endpoint was pathological response rate but only 26 patients of 30 evaluable underwent SLS. One patient did not undergo SLS due to clinical progressive disease; another patient refused surgery. Two patients had a macroscopic complete response after laparoscopy, but secondary laparotomy and systematic biopsies were not performed (due to patient refusal); therefore those patients were not considered as qualifying for complete pathological response. Of these 30 evaluable patients, only 11 patients were found to have pathological complete response (37%) at the second interim analysis, meeting criteria for stopping trial against the treatment.
By considering response according to the residual tumour volume after initial surgery, the pCR rates in optimally debulked patients (p5 mm) and suboptimally debulked or stage IV patients were 71% (5 of 7) and 31% (6 of 19), respectively.
Survival (Figures 2 and 3)
With a median follow-up of 42 months (2 to 58 months), the estimated five-year overall survival (Figure 2 ) is 40% (95% CI ¼ 24 to 67%). Median progression-free survival for patients in the study was 19 months (95% CI ¼ 18 to 26 months). Patients with optimal initial surgery had a significantly better median progression-free survival and trend toward better overall survival, than suboptimally debulked patients (Figure 3 ).
Discussion
HDC was originally developed in ovarian cancer as consolidation or salvage therapy in patients with prior conventional chemotherapy. 7, 8, [23] [24] [25] [26] [27] [28] [29] [30] Moreover, only a limited number of patients received this strategy as firstline treatment, essentially as consolidation after induction treatment. 8, 13, 23, 28, 31 Addressing this issue, the French GINECO group performed a randomised study evaluating the impact of a single course of HDC with autologous stem cell support as consolidation in AOC with low tumour burden following initial conventional chemotherapy, compared to 3 additional conventional chemotherapy cycles. Early results were in favour of a significant improvement in disease-free survival for HDC arm. 32 However, long-term results recently released as a poster communication were no longer statistically significant 33 and full publication of the mature data of this phase III trial is awaited.
We tried to design a phase II study using the dose-effect concept in a different and original way. We speculated that applying intensive and/or dose-dense chemotherapy as front-line treatment, without previous selection of patients on the basis of response to conventional chemotherapy, would increase the response rate by converting as responders a certain fraction of patients insensitive to standard dosage. In addition, we assumed that such an early intensive strategy might limit early emergence of drug-resistant cancer clones that contribute to relapse after treatment in spite of high initial response rates. This kind of approach may include not only ablative regimen requiring HSC support but also dose intensive multicycle chemotherapy, and was shown to be feasible and promising in various malignancies, including ovarian cancer. [12] [13] [14] [15] [16] [17] [34] [35] [36] [37] [38] [39] When investigated in AOC in a first-line setting by various Table 3 Haematological toxicity 21  18  5  3  17  2  2  Median number  2  2  2  2  2  2  2  2 a Number of patients experiencing toxicity. b Number of patients receiving erythrocyte transfusion. Front-line sequential HDC in ovarian cancer A Gonc¸alves et al pilot studies, these strategies were shown to be relatively safe and provided generally encouraging pCR rates ranging from more than 30 to 55%. Treatment delivery and toxicity data reported herein confirm that such a highly sophisticated approach is feasible as front line treatment in ovarian cancer, even in a multicentre setting, with very significant but manageable toxicity and without observed lethal events. Of 34 eligible patients, 30 completed 7 cycles and 28 received all cycles, with a median interval between cycle 1 and 8 of 4.5 months. Haematological toxicity was comparable to previously described sequential dose-dense chemotherapy regimen and required the expected level of supportive care including i.v. antibiotics and significant transfusion support. Relevant nephrotoxicity was observed in about 10% of carboplatin cycles, but was reversible in all cases. Other extra-haematopoietic toxicities were rare, including neurotoxicity which was grade 3/4 for only one patient.
Our primary endpoint was to increase the pathological response rate to 50%. This threshold was defined according to data from paclitaxel and cisplatin in the GOG-111 and European-Canadian Intergroup (OV10) trials, 2, 3 where pCR ranged between 20 and 40%, and was postulated as the acceptable improvement regarding the toxicity encountered. With a non-negligible pCR of nearly 40%, this objective was not reached and several remarks or comments can be made that may contribute to explain this failure.
First, it is noteworthy that two patients with negative final laparoscopy refused to undergo full laparotomy, as required by the study. If negative SLS had been confirmed after laparotomy in at least one of them, the trial would have included 15 additional patients, before concluding. Thus, if the trial was appropriately closed as initially planned, rejecting the treatment efficacy hypothesis, it is still possible that this hypothesis was actually true but missed by the study. Second, was the dosing level of our high-dose regimen high enough? This regimen was designed to achieve different objectives: to effectively mobilize HSC using high-dose cyclophosphamide and epirubicin, to deliver a high-dose of carboplatin with HSC, not as a consolidation but earlier in the treatment course alternating with dose dense paclitaxel. However, total carboplatin dose administered in our study was 36 mg/ml/min (AUC ¼ 18 mg/ml/ min Â 2), which is relatively comparable to cumulative dose of carboplatin in standard dose treatment (AUC 6 mg/ml/ min Â 6). In addition, second administration of highdose carboplatin was scheduled 56 days after the first, 
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A Gonc¸alves et al leading to a rather conventional carboplatin dose-intensity of 2.25 mg/ml/min per week. With an administration at 15 day-intervals, paclitaxel was relatively dose-dense. However, it was used at a moderately increased dose level and paclitaxel cumulative dose was 800 mg/m 2 , less than total paclitaxel given after standard chemotherapy (1050 mg/m 2 ¼ 175 mg/m 2 Â 6). Third, the first administration of carboplatin was performed on day 42, while paclitaxel sequences were initiated on day 63, which can be quite late. In addition, even though alkylating agents like cyclophosphamide are considered to be active drugs in ovarian cancer and were part of standard chemotherapy regimen used in the pre-taxanes era, 40 the activity of anthracyclines in ovarian cancer remains controversial. Indeed, if meta-analyses have suggested a significant survival impact of adriamycin, 41 there have been several negative comparative studies. [42] [43] [44] Thus, it is possible that the initial high-dose cyclophosphamide-based mobilisation phase could have resulted in an actual delay in the administration of the 2 most active drugs. This may have negatively impacted on results, especially in view of some data suggesting that early chemotherapy after surgery could be associated with a better outcome, 45 although this hypothesis remains largely controversial in ovarian cancer. 46, 47 Finally, population included in the study was clearly a poor prognosis population with more than 50% of patients having suboptimal surgical debulking and nearly one third having stage IV disease. In our population, pCR was around 71% in optimally debulked patients, but only 31% in the remaining patients. A study from the Memorial Sloan-Kettering Cancer Center using a HSC mobilisation course and three cycles of high-dose carboplatin/paclitaxel combinations with one cycle of terminal high-dose melphalan, as first-line treatment in AOC found a pathological complete response rate of 34% very similar to the one reported in our study. 13 Interestingly, by considering a subgroup of patients with previous optimal debulking surgery, they reported a pCR of 55%, compared to only 13% in suboptimal stage III or stage IV patients. In an Australian phase I trial evaluating front-line sequential HDC using topotecan, carboplatin and paclitaxel, a pCR was found in 8 of 16 evaluable AOC patients. 35 Similarly, the majority of these pCRs were observed in patients with 'optimally' debulked disease.
Consequently, our results as well as negative results from the GINECO trial should not be taken to indicate that all HDC regimens do not provide any advantage in all subgroups of ovarian cancer patients. Rather, it is possible that benefits from administration of HDC could be optimised by a different drug administration schedule, with earlier introduction of most effective drugs than in our study. Moreover, the impact of this kind of approach could be more obvious if applied only to patients with minimal tumour burden. Of note, this subset of patients is also the most likely to reach a high pCR after conventional chemotherapy and only carefully designed controlled studies may clearly determine the place of intensive treatment in this subgroup of patients. Finally, similarly to other cytotoxic strategies, it would be critical to identify biologically-defined subgroups of tumours that could derive the highest benefit from dose-dense approaches, allowing to restrict such an aggressive strategy only to a population with high probability of response.
In conclusion, we reported a phase II study of front-line intensive sequential HDC with HSC in AOC. Procedure was feasible in a multicentre setting, with significant but manageable toxicities. Our primary endpoint, i.e. to provide a substantial increase in pCR, was not reached. Therefore, regarding the high level of toxicity encountered, such an approach should not be performed outside clinical trials but remains an experimental strategy to further optimise.
